260 related articles for article (PubMed ID: 32614401)
1. Association Between Common Vaginal Infections and Cervical Non-Human Papillomavirus (HPV) 16/18 Infection in HPV-Vaccinated Women.
Hu SY; Tsang SH; Chen F; Pan QJ; Zhang WH; Hong Y; Sampson JN; Hildesheim A; Zhao FH; Kreimer AR
J Infect Dis; 2021 Feb; 223(3):445-451. PubMed ID: 32614401
[TBL] [Abstract][Full Text] [Related]
2. Associations Between Vaginal Infections and Potential High-risk and High-risk Human Papillomavirus Genotypes in Female Sex Workers in Western Kenya.
Menon S; Broeck DV; Rossi R; Ogbe E; Harmon S; Mabeya H
Clin Ther; 2016 Dec; 38(12):2567-2577. PubMed ID: 27836494
[TBL] [Abstract][Full Text] [Related]
3. Co-infection with trichomonas vaginalis increases the risk of cervical intraepithelial neoplasia grade 2-3 among HPV16 positive female: a large population-based study.
Yang M; Li L; Jiang C; Qin X; Zhou M; Mao X; Xing H
BMC Infect Dis; 2020 Sep; 20(1):642. PubMed ID: 32873233
[TBL] [Abstract][Full Text] [Related]
4. [Association of human papillomavirus infection with other microbial pathogens in gynecology].
Zheng MY; Zhao HL; Di JP; Lin G; Lin Y; Lin X; Zheng MQ
Zhonghua Fu Chan Ke Za Zhi; 2010 Jun; 45(6):424-8. PubMed ID: 21029592
[TBL] [Abstract][Full Text] [Related]
5. An association between Trichomonas vaginalis and high-risk human papillomavirus in rural Tanzanian women undergoing cervical cancer screening.
Lazenby GB; Taylor PT; Badman BS; McHaki E; Korte JE; Soper DE; Young Pierce J
Clin Ther; 2014 Jan; 36(1):38-45. PubMed ID: 24417784
[TBL] [Abstract][Full Text] [Related]
6. Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.
Lang Kuhs KA; Gonzalez P; Rodriguez AC; van Doorn LJ; Schiffman M; Struijk L; Chen S; Quint W; Lowy DR; Porras C; DelVecchio C; Jimenez S; Safaeian M; Schiller JT; Wacholder S; Herrero R; Hildesheim A; Kreimer AR;
J Infect Dis; 2014 Dec; 210(12):1890-9. PubMed ID: 24958910
[TBL] [Abstract][Full Text] [Related]
7. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
8. Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.
Safaeian M; Sampson JN; Pan Y; Porras C; Kemp TJ; Herrero R; Quint W; van Doorn LJ; Schussler J; Lowy DR; Schiller J; Schiffman MT; Rodriguez AC; Gail MH; Hildesheim A; Gonzalez P; Pinto LA; Kreimer AR;
J Natl Cancer Inst; 2018 Feb; 110(2):205-12. PubMed ID: 28954299
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
10. Atypical Squamous Cells in Liquid-Based Cervical Cytology: Microbiology, Inflammatory Infiltrate, and Human Papillomavirus-DNA Testing.
Gomes de Oliveira G; Eleutério RMN; Silveira Gonçalves AK; Giraldo PC; Eleutério J
Acta Cytol; 2018; 62(1):28-33. PubMed ID: 29130974
[TBL] [Abstract][Full Text] [Related]
11. Assessing the reduction of viral infectivity in HPV16/18-positive women after one, two, and three doses of Gardasil-9 (RIFT): Study protocol.
López-Codony V; de Andrés-Pablo Á; Ferrando-Díez A; Fernández-Montolí ME; López-Querol M; Tous S; Ortega-Expósito C; Torrejón-Becerra JC; Pérez Y; Ferrer-Artola A; Sole-Sedeno JM; Grau C; Rupérez B; Saumoy M; Sánchez M; Peremiquel-Trillas P; Bruni L; Alemany L; Bosch FX; Pavón MA
PLoS One; 2024; 19(5):e0304080. PubMed ID: 38768231
[TBL] [Abstract][Full Text] [Related]
12. Risks for cervical abnormalities in women with non-16/18 high-risk human papillomavirus infections in south Shanghai, China.
Wang X; Wu S; Li Y
J Med Virol; 2021 Nov; 93(11):6355-6361. PubMed ID: 34232523
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.
Zhu FC; Hu SY; Hong Y; Hu YM; Zhang X; Zhang YJ; Pan QJ; Zhang WH; Zhao FH; Zhang CF; Yang X; Yu JX; Zhu J; Zhu Y; Chen F; Zhang Q; Wang H; Wang C; Bi J; Xue S; Shen L; Zhang YS; He Y; Tang H; Karkada N; Suryakiran P; Bi D; Struyf F
Cancer Med; 2019 Oct; 8(14):6195-6211. PubMed ID: 31305011
[TBL] [Abstract][Full Text] [Related]
14. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.
Nygård M; Hansen BT; Dillner J; Munk C; Oddsson K; Tryggvadottir L; Hortlund M; Liaw KL; Dasbach EJ; Kjær SK
PLoS One; 2014; 9(2):e88323. PubMed ID: 24505474
[TBL] [Abstract][Full Text] [Related]
15. Distribution of human papillomavirus (HPV) genotypes and bacterial vaginosis presence in cervical samples from Paraguayan indigenous.
Mongelos P; Mendoza LP; Rodriguez-Riveros I; Castro A; Gimenez G; Araujo P; Paez M; Castro W; Basiletti J; González J; Echagüe G; Diaz V; Laspina F; Ever S; Marecos R; Deluca G; Picconi MA
Int J Infect Dis; 2015 Oct; 39():44-9. PubMed ID: 26283550
[TBL] [Abstract][Full Text] [Related]
16. Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.
Beachler DC; Kreimer AR; Schiffman M; Herrero R; Wacholder S; Rodriguez AC; Lowy DR; Porras C; Schiller JT; Quint W; Jimenez S; Safaeian M; Struijk L; Schussler J; Hildesheim A; Gonzalez P;
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26467666
[TBL] [Abstract][Full Text] [Related]
17. Effects of 2 and 3 Vaccinations With the Bivalent Human Papillomavirus (HPV) Vaccine on the Prevalence and Load of HPV in Clearing and Persistent Infections in Young Women.
van Eer K; Middeldorp M; Dzebisasjvili T; Lamkaraf N; de Melker HE; Steenbergen RDM; King AJ
J Infect Dis; 2023 Oct; 228(8):1012-1022. PubMed ID: 36988110
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica.
Coseo S; Porras C; Hildesheim A; Rodriguez AC; Schiffman M; Herrero R; Wacholder S; Gonzalez P; Wang SS; Sherman ME; Jimenez S; Solomon D; Bougelet C; van Doorn LJ; Quint W; Safaeian M;
Sex Transm Dis; 2010 Nov; 37(11):706-14. PubMed ID: 20661178
[TBL] [Abstract][Full Text] [Related]
19. Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study.
Oakeshott P; Aghaizu A; Reid F; Howell-Jones R; Hay PE; Sadiq ST; Lacey CJ; Beddows S; Soldan K
BMJ; 2012 Jun; 344():e4168. PubMed ID: 22730542
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus infection in females with normal cervical cytology: Genotyping and phylogenetic analysis among women in Punjab, Pakistan.
Aziz H; Iqbal H; Mahmood H; Fatima S; Faheem M; Sattar AA; Tabassum S; Napper S; Batool S; Rasheed N
Int J Infect Dis; 2018 Jan; 66():83-89. PubMed ID: 29138009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
